Endurobol (Cardarine)

Description

Description du produit :

Magnus Endurobol (GW501516) is a PPAR modulator known for enhancing endurance and promoting fat loss. It effectively stimulates glucose absorption into skeletal muscle tissue and at the same time encourages the oxidation of fatty acids. Along with these main benefits, the product has a range of health benefits backed by extensive scientific research.

Uses and Benefits:

Magnus Endurobol is primarily used by athletes and bodybuilders, particularly during their cutting cycles. Its key benefits include improving endurance levels and promoting fat loss. This product is extremely beneficial for those performing cardio regularly and it also enables easier and longer weight training sessions. It helps maintain a high performance level for extended periods. Apart from these, the product also contributes to increased vascularization for a lean and shredded look, even without being on a diet.

Magnus Endurobol is promising as a potential obesity treatment due to its quick fat-dissolving properties. In phase II trials, it has demonstrated the ability to increase HDL (good cholesterol) by an average of 79% and decrease LDL (bad cholesterol).

Caractéristiques du produit :

• Magnus Endurobol is a PPAR6 agonist.
• The product has been studied for over 20 years and has not shown any side effects.
• Magnus Pharmaceuticals ensures very selective control over the product’s originality and quality.

Recommandations posologiques :

It is recommended to take 2 to 4 capsules of Magnus Endurobol per day. The capsules should be taken 45-60 minutes prior to exercising to maximize the effects during training. If one is not training, the dosage can be divided throughout the day.

Combination:

Magnus Endurobol can be combined with other Sarms like Andarine and Ostarine (MK-2866) for cutting cycles. As it doesn’t affect hormones, it can be safely used by women.

1. Hussein, M., & Deshpande, S. (2009). GW501516 [Internet]. In: Molecular Imaging and Contrast Agent Database (MICAD). Gobierno de los Estados Unidos de América.
2. Fan, W., & Evans, R. (2017). PPARs and ERRs: molecular mediators of mitochondrial metabolism. Current Opinion in Cell Biology, 45, 1-6.
3. Olson, E. J., Pearce, G. L., Jones, N. P., & Sprecher, D. L. (2012). Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology, 32(9), 2289-2294.
4. Seki, T., Hosaka, T., Fischer, C., Lim, S., Andersson, P., Abe, M., … & Hellström, M. (2019). Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning. Journal of Experimental Medicine, 215(2), 611-626.
5. Varga, T., Czimmerer, Z., & Nagy, L. (2011). PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1812(8), 1007-1022.
6. King, V., & Sennitt, M. V. (2007). Endurobol (GW501516) : Peroxisome Proliferator Activated Receptor δ (PPARδ) Agonist—Acute Cardiovascular Effects in the Stroke-Prone Spontaneously Hypertensive Rat. European Journal of Clinical Investigation, 37(12), 933–939.
7. Sprecher, D. L., Pearce G. L., Harris W. S. (2017). Cardarine (GW 501516) Increases the Expression of Fat Oxidation Genes in Skeletal Muscle of Obese Mice. The American Journal of Clinical Nutrition, 96(3), 568–576.
8. Rufo, C., Teran, G., O